	US 12,258,378 B2
	Engineered cells, T cell immune modulating antibodies and methods for using the same
Wayne A. Marasco, Wellsley, MA (US); Quan Karen Zhu, Southborough, MA (US); and Emily Kuiper, Boston, MA (US)
Assigned to Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Appl. No. 16/980,742
Filed by Dana-Farber Cancer Institute, Inc., Boston, MA (US)
PCT Filed Mar. 14, 2019, PCT No. PCT/US2019/022272 § 371(c)(1), (2) Date Sep. 14, 2020, PCT Pub. No. WO2019/178356, PCT Pub. Date Sep. 19, 2019.
Claims priority of provisional application 62/657,151, filed on Apr. 13, 2018.
Claims priority of provisional application 62/643,040, filed on Mar. 14, 2018.
Prior Publication US 2021/0163570 A1, Jun. 3, 2021
Int. Cl. C07K 14/705 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01)

CPC C07K 14/705 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464421 (2023.05); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2866 (2013.01); C12N 5/0636 (2013.01); A61K 2239/23 (2023.05); A61K 2239/29 (2023.05); A61K 2239/49 (2023.05); C07K 2317/565 (2013.01); C12N 2510/00 (2013.01)]

19 Claims

1. An engineered cell comprising a nucleic acid encoding a chimeric antigen receptor, wherein the chimeric antigen receptor is specific for two or more antigens on the surface of a cancer cell, wherein the two or more antigens comprise CXCR4 and claudin-4, wherein the chimeric antigen receptor comprises:

a VH with a CDR1 comprising GFTVSSNY (SEQ ID NO: 59); CDR2 comprising IYSGGST (SEQ ID NO: 60); and CDR3 comprising ARDNPLSAFDI (SEQ ID NO: 61); and

a VL with a CDR1 comprising QSINSW (SEQ ID NO: 62); CDR2 comprising KAS (SEQ ID NO: 63); and CDR3 comprising QQYDDLPLT (SEQ ID NO: 64).